# Bone Resorption, Osteoclastogenesis and Adalimumab

> **NCT02035800** · PHASE4 · UNKNOWN · sponsor: **Université de Sherbrooke** · enrollment: 120 (estimated)

## Conditions studied

- RheumatoId Arthritis

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02035800
- **Lead sponsor:** Université de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035800, "Bone Resorption, Osteoclastogenesis and Adalimumab". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02035800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*